Share
+1
Share

Article

February 7, 2018

Avatar

Tiash Saha
1679 views
KEY POINTS The new drug approved by FDA targets hard-to-treat, a rare form of pancreatic cancer. It is the same ...
Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Get 1-Month Free Subscription

Access articles & resources worth up to $4000.

Already have an account?
Categories: NEW DRUG APPROVAL, NEWLY PUBLISHED, News from Europe
Tags: , , , , , , ,
KEY POINTS The new drug approved by FDA targets hard-to-treat, a rare form of pancreatic cancer. It is the same ...

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Get 1-Month Free Subscription

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Get 1-Month Free Subscription

Access articles & resources worth up to $4000.

Already have an account?

More in NEW DRUG APPROVAL

BRIEFING

First Oral Drug Reducing Risk of Blood Loss in Liver Disease Patients Gets Approved

2016 founded company, Dova Pharma's first drug, Doptelet received US FDA approval as the first oral treatment option to reduce the risk of blood loss in patients with chronic liver disease.

NEW DRUG APPROVAL

First Migraine-Preventing Drug ‘Aimovig’ Bags FDA Approval

Much conversation and research were going on over a couple of years on a new class of drug- CGRP inhibitors and its potential to prevent and treat a migraine. The US FDA has approved the first treatment- Aimovig (erenumab-aooe) to prevent migraine in adults, belonging to the new class of drug called CGRP inhibitors. Aimovig is developed by Amgen. Read the article to know about Aimovig and developments in the popular area of migraine research- CGRP inhibitors.

BRIEFING

First Drug to Treat Polycystic Kidney Disease Bags FDA Approval

First drug treatment- Jynarque (tolvaptan) to slow down the decline in kidney function in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) received USFDA approval. The drug is developed by Japanese biopharma, Otsuka Pharma.

NEW DRUG APPROVAL

Drug Innovation: FDA Approves Seven New Drugs in Four Months (Jan-Apr 2018)

Within first four months of 2018, seven new drugs are already approved by the FDA for a wide range of diseases including HIV, psoriasis, and rare cancers. 2018 will also see the first ever “game-changing” CRISPR gene editing clinical trial in humans.

Most Popular

GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?

NEWLY PUBLISHED

Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.